retatrutide black market CNBC investigates the of obesity drugs June 8, 2026: Reckless physicians

Tirzepatide (Zepbound): Showed up to 20.9% average weight reduction at the highest dose in the SURMOUNT-1 trial

H., Navarria, A

If you are also taking insulin or a sulfonylurea, be aware that adding any incretin-based therapy may increase the risk of hypoglycaemia

reinstated December 2025 (status: monitor closely) States that restrict coverage: Michigan restricted to BMI 40 (morbid obesity) with strict prior authorization criteria

13mL of bacteriostatic water per vial is standard for most research protocols

5 In summary, while Berberine shows promise, experts advocate for regulated clinical use, appropriate patient selection, and more rigorous studies to validate its safety and efficacy across broader populations